Medical and Science
Loss of smell ‘first sign’ of COVID-19, experts say

Medical News: Medical experts in countries hit by COVID-19 are reporting the first tell-tale signs of the virus may be in an unexpected loss in smell.
Ear, nose and throat (ENT) surgeons say loss of smell – as the virus causes swelling in the olfactory mucosa more than other viruses – could be used as a key clinical indicator in otherwise symptom-free carriers of COVID-19.
“It is these ‘silent carriers’ who may remain undetected by current screening procedures, which may explain why the disease has progressed so rapidly in so many countries around the world,” says South Australian specialist Flinders University Professor Simon Carney, from the Southern ENT and Adelaide Sinus Centre.
“While further research is required, loss of smell, or anosmia, has been reported in as many as 1 in 3 patients in South Korea and, in Germany, this figure was as high as 2 in patients,” says Professor of Otolaryngology (head and neck surgery) at Flinders University.
Register FREE and join 20,000+ industry professionals who receive the latest industry news, innovations and insights from Health Industry Hub; the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.
“An ENT professor in London has reported seeing a dramatic increase in patients with anosmia as their only symptom of COVID-19 infection.”
As Australia struggles to contain the spread of COVID-19, identification of these carriers could help to slow the spread of infection.
“In the UK, ENT surgeons are pushing to have anosmia highlighted as an important symptom that may signify a patient may be an asymptomatic carrier,” says Professor Carney, immediate past president of the Australia and New Zealand Rhinologic Society.
“Australia is in a position to take advantage of these findings overseas to try and ‘flatten the curve’ while we still can.”
Doctors and COVID-19 detection centres could use this subtle sign and unexplained sudden anosmia in the testing criteria, he says.
Patients should also consider calling their GP with this early symptom as a precursor for possible treatment.
HCP engagement during COVID-19. Health Industry Hub combines expertise in target audience insights, delivering digital health content and measuring engagement with 20+ years industry experience. Created by industry for industry.
Digital & Innovation
Health sector faces new privacy obligations
Healthcare organisations must update their privacy policies by 10 December if they use artificial intelligence (AI) or a computer program […]
MoreNews - Pharmaceuticals
TGA approves new antibiotic but AMR blind spot remains a critical concern
The Therapeutic Goods Administration (TGA) has approved a new antibiotic for the treatment of carbapenem-resistant Gram-negative bacterial infections. Developed by […]
MoreNews - MedTech & Diagnostics
BCAL Diagnostics rejects merger speculation
ASX-listed BCAL Diagnostics has moved to quash speculation of a potential three-way merger involving Genetic Signatures and Microba Life Sciences, […]
MoreNews - Pharmaceuticals
Australia backs infectious disease innovation as US funding faces more cuts
Biointelect Venturer, a national incubator supporting infectious disease innovation, will open its second funding round later this month, with AUD […]
More